10.24335/L24741
RoyaltyStat
Research program, with exclusive patent, know-how and technology license to manufacture, have manufactured, develop, use, sell, import, distribute, and sublicense altered peptide ligand compounds to diagnose, treat and prevent multiple sclerosis in humans by modulating the immune response to neuro antigens, with exclusive marketing rights worldwide except North America.
RoyaltyStat
1996